Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we’ll conduct a question-and-answer session. This call is being recorded on Thursday August 10, 2023. I would now like to turn the conference over to, Robert Uhl, ICR Westwicke. Please go ahead.

Thank you, operator, and good afternoon to everyone on the call. Thank you for joining us to review Celcuity’s second quarter 2023 financial results and business update. Earlier today, Celcuity released financial results for the second quarter ending June 30, 2023. The press release can be found on the Investors section of the company website. Joining me on the call today are Brian Sullivan, Celcuity’s Chief Executive Officer and Co-Founder; Vicky Hahne, Chief Financial Officer; as well as Igor Gorbatchevsky, Chief Medical Officer, who will be available during Q&A. Before we begin, I would like to remind listeners that our comments today will include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today’s press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in the forward-looking statements. Such forward-looking statements and their implications involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. On this call, we will also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company’s current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors’ understanding and assessment of the company’s ongoing core operations and prospects for the future. You can find the table reconciling the non-GAAP financial measures to GAAP measures in today’s press release. And with that, I would now like to turn the call over to Brian Sullivan, CEO of Celcuity. Please go ahead.

Thank you, Robert, and good afternoon to everyone joining us on today’s call. Our top priority this quarter was continuing to execute enrollment activities at trial sites globally for our VIKTORIA-1 Phase 3 clinical trial. As we’ve discussed previously, VIKTORIA-1 is evaluating our lead compound gedatolisib combined with fulvestrant, with or without palbociclib in patients with HR+/HER2- advanced breast cancer whose disease progressed while receiving a CDK4/6 inhibitor. We are pleased to report that we now have nearly 200 trial sites recruiting patients in 20 countries. Throughout the first half of this year, our team has done a fantastic job of coordinating with regulatory authorities and individual sites to ensure our sites can begin recruiting patients as quickly as possible. They’re relentlessly focused on keeping us on track to report the primary analysis for the PI3K non-mutated patient subgroup in the second half of 2024, and the primary analysis for the PIK3CA mutated patient subgroup in the first half of 2025. This is consistent with our previously discussed expectations. We’re seeking to improve outcomes for a patient population that receives limited benefit from current second line standard of care therapies. We estimate that this initial potential target population represents over 100,000 breast cancer patients globally on an annual basis. Current standard of care for these patients includes endocrine therapies such as fulvestrant and regimens that combine fulvestrant with an mTOR specific or PI3Kα specific targeted therapy. These therapies offer only modest progression-free survival periods, and in the case of the approved PI3Kα inhibitor, a very challenging safety profile. The significant unmet need for these breast cancer patients has led to the development and subsequent investigation of a significant number of new therapies aimed at these patients. An oral SERD for patients with an ESR1 mutation was recently approved and an AKT inhibitor reported positive results from its Phase 3 study late last year. Median PFS for these two new therapies ranged from 3.8 to 5.5 months in our patient population. While the availability of new drug alternatives for patients is always good news based on the results reported for these drugs, the unmet need for these patients will still remain. As we’ve discussed previously, there’s a general consensus among leading breast cancer researchers that HR+/HER2- breast cancer involves the estrogen CDK4/6 and PI3K/mTOR pathways, each of which can cross-activate the other. To most effectively treat this disease, we believe data from our Phase 1b study strongly suggests that simultaneous inhibition of these three pathways is required to optimize outcomes for these patients. And to date randomized studies have consistently shown that partial inhibition of the PI3K/mTOR pathway with drugs that only target a single component of this pathway, such as ones that target PI3Kα, AKT, or mTORC1 can provide only modest anti-tumor effects when patients have progressed on prior CDK4/6 treatment. Thus, we believe gedatolisib's highly differentiated mechanism of action as an equipotent PI3K/mTOR inhibitor is uniquely suited to most effectively address this unmet need, especially since gedatolisib has demonstrated activity independent of the presence of PIK3CA or ESR1 mutations in a patient’s tumor. Our confidence that gedatolisib can play an important role in improving outcomes for women with HR+/HER2- advanced breast cancer was reinforced with the updated PFS data we reported at the ESMO Breast Cancer Congress in May for first-line patients from our Phase 1b study. Treatment-naïve patients with HR+/HER2- advanced breast cancer treated with gedatolisib, palbociclib, and letrozole obtained a median progression-free survival period of 48.6 months and 79% reported an objective response. Outcomes were comparable for patients with and without PIK3CA mutations highlighting the rationale for comprehensive as opposed to selective inhibition of the PI3K/mTOR pathway. These results compare very favorably to the median PFS of 24.5 months and the 55% objective response rate reported in the PALOMA-3 study for palbociclib plus letrozole. We believe the data suggests gedatolisib has the potential to eventually become a first-line treatment option. Last year, we began evaluating and prioritizing new potential indications for gedatolisib. We assessed previous trials for other PI3K and mTOR inhibitors and characterized the activity of gedatolisib and other PI3K, AKT, mTOR inhibitors in different hormonally driven tumor types. Our initial results from non-clinical studies in prostate cancer were presented at ASCO GU in February and in gynecological cancers at AACR in April. In each of these studies, gedatolisib exhibited superior activity relative to all of the other PI3K, AKT, mTOR inhibitors evaluated. Thus based on the review of prior clinical studies with PI3K, AKT, and mTOR inhibitors and our assessment of the relative advantages gedatolisib’s mechanism of action provides, we believe there is a significant opportunity for us to develop gedatolisib in these additional tumor types over time. We expect to provide you with an update on our pipeline development strategy by the end of the third quarter. Now, I’d like to shift our discussion to the diagnostic side of our business. It centers on CELsignia, our third-generation diagnostics platform. Our FACT-1 and FACT-2 trials are ongoing and enrolling patients with early-stage HR+/HER2- breast cancer, whose HER2 pathway is hyperactive as detected with our CELsignia test. We continue to expect to announce interim results from these studies in the first half of 2024.

Thank you, Brian, and good afternoon to everyone. I’ll provide a brief overview of our second quarter 2023 financial results. The second quarter net loss was $14.6 million or a $0.66 loss per share compared to a net loss of $10 million or a $0.67 loss per share for the second quarter 2022. Because these quarterly net losses include significant non-cash items including stock-based compensation and interest expense, we also include in our press release non-GAAP adjusted net loss for the quarter ending June 30, 2023. Our non-GAAP adjusted net loss for the second quarter of 2023 was $12.8 million or a $0.58 loss per share compared to a non-GAAP adjusted net loss for the second quarter of 2022 of $8.3 million or a $0.55 per share. Research and development expenses were $13.7 million for the second quarter of 2023 compared to $8.4 million for the second quarter of 2022. The approximately $5.4 million increase during the second quarter of 2023 primarily resulted from costs supporting activities related to the VIKTORIA-1 pivotal trial. We expect this expense to increase over the next two quarters consistent with the increase between Q2 and Q1 of 2023, again, primarily due to activities associated with VIKTORIA-1. At that point, we expect expenses to remain roughly flat in 2024. General and administrative expenses were $1.3 million for the second quarter of 2023 compared to $1.2 million for the second quarter of 2022. Net cash used in operating activities for the second quarter of 2023 was $9.7 million compared to $11.3 million for the second quarter of 2022. This was a result of a non-GAAP adjusted net loss of approximately $12.8 million offset by working capital changes of approximately $1.4 million and changes in cash received from interest income related to maturities of short-term investments of approximately $1.7 million. We ended the quarter with approximately $146.2 million of cash, cash equivalents, and short-term investments compared to $168.6 million at December 31, 2022.

Thank you, Vicky. Operator, we’re ready to take questions if there are any.

Thank you. Ladies and gentlemen, we will now conduct the question-and-answer session. Your first question comes from the line of Maury Raycroft from Jefferies. Your line is now open.

Hi, thanks for taking my questions. I was just going to ask for the Phase 3, if there’s any additional perspective you can share on how enrollment is going based on types of patients potentially how it relates to wild type versus mutant patients and also geographic regions.

So we’re enrolling patients consistently in all the regions and just some regions as expected will be more active than others, but we’re not breaking that out just at this point in time. But so far activities are proceeding as we expected. The site activations have gone well. The startups have gone well and the sites are engaged.

Got it. Okay. And you mentioned that you’re recruiting at nearly 200 sites in 20 countries. Are you going to open additional sites or are you satisfied with the current number of sites open and enrollment rate? I guess any additional perspective there?

We have some additional sites in the pipeline and so in some ways, they act as backup, because not every site does exactly what you’d like. And so we will over in effect activate – we will activate more than 200 sites to anticipate that some of these sites might not be as productive as we’d like.

Got it. Okay. And one more question, and then I’ll hop back in the queue. I think you said in the past, there could be data this year supporting the three-week on and one week off dosing schedule, which allows for the immune system holiday. When and in what form should we expect to see data from that?

Well, I think what we said was that we would have some data – animal data that would show immune system activity that we think is consistent with what occurs during the one week off dose period with the three-week on, one week off schedule. And we expect to cover that when we provide an update on our overall pipeline, our R&D Day or so to speak, which will happen we think before the end of this quarter.

Got it. Okay. Thanks for taking my questions.

You’re welcome.

Your next question comes from the line of Boris Peaker from Cowen. Your line is now open.

Great. Thanks for taking my question. My first question is on the VIKTORIA-1 trial. So my understanding that arm A is the key triplet arm in the study, which you plan to compare to arm C. I’m just curious, does the success or failure of arm B really matter here?

So arm B is intended to serve two purposes. One is to potentially support a registration of gedatolisib plus fulvestrant. And at that analysis, B versus C is powered independently and is going to be tested as a primary analysis. The second is, it helps demonstrate the contribution of gedatolisib and allows analysis of the contribution of palbociclib. And so you will see or you want to see some form of arithmetic difference between those three arms, but they don’t statistically for purposes of supporting an A versus C comparison need to be significant.

Great. And my second question also on the VIKTORIA trial. Do you have a sense of the dropout rate at this point, maybe even on a blinded basis altogether?

We don’t. I mean, we have – again, this early in the study, you get there’s two factors, right? There’s progression and then there’s dropout due to factors other than progression. We made assumptions in the trial that are probably pretty consistent with assumptions other companies make and there’s nothing that we’ve seen to date that would suggest there’s anything different than what our assumptions were in terms of – that would help inform a projection of primary analysis.

Great. Thanks for taking my question.

You’re welcome.

Your next question comes from the line of Gil Blum from Needham and Company. Your line is now open.

Hello and good afternoon, Brian.

Hi, Gil.

So maybe a quick one on, you mentioned a couple of agents that have had data recently. Assuming those are potentially approved at some point, could that change the therapeutic landscape for gedatolisib combos? Thank you.

Thanks for the question. We don’t think so because the benefit that’s being reported isn’t substantially better than what’s currently available. In the case of the AKT inhibitor that reported data in this patient population, if you’re doing a cross-trial comparison, at least it appears that it’s not – it’s comparable. The data suggests maybe not as good as the PSK-alpha inhibitor that’s available. It has a better safety profile. So I’m sure the argument will be made that it can offer comparable anti-tumor control with less toxicity. But it may be a legitimate and good alternative for patients in light of the current standard of care. But we don’t think it necessarily changes or raises a threshold of outcome for patients receiving these therapies.

Gil, we can’t hear you if you’re still – if you’re asking another question?

Thank you, Brian. That’s my only question.

Okay. Okay. Thanks.

Your next question comes from Alex Nowak from Craig-Hallum Capital Group. Your line is now open.

Hi. Good afternoon everyone. This is Albert Hu on for Alex. So a question regarding VIKTORIA, and with the enrollment ramping and with you guys looking at other cancer indications, what additional investments in talent and resources do you need to plan for?

Sure. So we closed the pipe transaction late last year that raised $100 million. And the intention of that pipe was to fund the VIKTORIA-1 study through data readout as well as to fund an early phase study in another tumor type. And the cost of an early phase study is certainly relatively very modest relative to a Phase 3 study and very modest in the scheme of things. And so the guidance we’ve provided about our cash runway has been through the end of 2025, and we’re still confident that’s where we’ll end up.

Got you. Thank you. And as enrollment increases higher, what sort of recruitment protocols changes have you made? Or have you stuck to the same?

I’m sorry. Did you say recruitment protocol? No, the activity that we’ve started the study with and continuing and the overall approach to ensure patients are identified as early as possible. That’s to cite the trial visibility at the site that patients are identified well in advance. That’s been part of our strategy from Day 1, and that’s what we’re sticking with, and it’s proven effective. We try to work as best as we can with each of the sites to prescreen candidates or patients who are currently receiving CDK4/6 and those could be candidates for our study. We asked them to quantify that, so they actually – we know that they’ve gone to their charts and identified patients. And then we try to monitor that to see if those numbers are changing. And that just helps us get a sense of the flow as well as whether or not the site is engaged. Each of our sites gets a visit every two weeks from a clinical research associate to monitor activities in this study, but also to assess whether the study site is engaged overall and the recruitment activities or if everything is proceeding as should be. And so we feel we have a very good footprint in the site. We’re in regular contact. We separately establish contact and routine calls with the principal investigators at each of the sites. And so far, again that’s if you were to talk to people in this area, the engagement of the principal investigator plays a very, very significant role in how well a study accrues at that site, as well as the engagement of the study coordinator, who typically reports directly to the PI or to an organization. And so having those two individuals engaged is critical, and so those are among other things. The people we try to pay a lot of attention to and keep track of and ensure that to the extent they have questions or things come up that we’re able to respond as quickly as possible.

Got you. And one last question here. So I believe you mentioned this briefly, but just to reiterate. In the sites that are live, what is the cadence of enrollment? And is it still tracking along well with your expectations?

Sure. Each site is different. Some sites are community sites, some sites are very large, and some sites just are typically better at keeping track of patients and therefore getting them in the queue for screening to be considered, to be evaluated as a potential candidate. And so each site will – you’ll have a distribution of results across the number of sites that you have. And it’s not quite the 80/20 rule but you always have you’re A, it’s like anything in life, right? You’ll have your A accounts, your B accounts, and your C accounts, and you manage accordingly. And so we’re to be frank very pleased with the general level of activity at all the sites; so so far so good.

Thank you. That’s all my questions.

There are no further questions at this time. I will now turn the call over to Brian Sullivan, Chief Executive Officer. Please go ahead, sir.

Well, thank you. We appreciate your attending the call. I appreciate the questions and look forward to updating you in the future. Goodbye.

Ladies and gentlemen, this concludes today’s conference call. Thank you for your participation. You may now disconnect.